“An Unrelenting Disaster Zone”: Merck’s Alzheimer’s Drug Fails in Phase III Post author:Sam Post published:February 13, 2018 Post category:BioPharma Alzheimer’s drug development took another hit. Source: BioSpace You Might Also Like Despite Recent Layoffs, Eli Lilly to Invest $850 Million in U.S. Operations March 23, 2017 Cellular Biomedicine Group Plans Grand Opening Of Its New Shanghai Facility September 21, 2017 FDA Clears Expanded Indication for Medtronic's Freezor Xtra Cryoablation Catheter February 16, 2017
